CTE Sessions at EANM’16

EANM’16 – Mini Course I

October 16, 2016, 14:30 – 15:30
Updates in Radiopharmaceuticals for SPECT

Chairpersons: M.C. Attard (Nijmegen), L. Camoni (Brescia)


Speakers:
extended
abstract
P. Laverman (Nijmegen):
SPECT Radiopharmaceuticals: In-111-Exendin, an Example from Preclinical to Clinical studies
J. Sosabowski (London):
SPECT Radiopharmaceuticals: An Update


Educational objectives:

  1. To understand the principles of a radionuclide and a radiopharmaceutical
  2. Include the important aspects of Good Radiopharmaceutical Practice (GRP)
  3. Emphasize the importance of Quality Assurance and Quality Control
  4. Highlight the radiopharmaceuticals that are mostly used in SPECT
  5. Illustrate and clarify what a peptide is and why it is chosen for clinical trials
  6. Demonstrate the developments from clinical trials to clinical practice
  7. Why Exendin has been chosen for clinical trials
  8. How research with Exendin has resulted in a place in clinical practice


Summary:

A good nuclear medicine examination begins with a proper radiolabelling technique, which should be in accordance with all required radiopharmaceutical legislation and practice. Production and development of radiopharmaceuticals is a continuously changing and ongoing process, which is why technologists and radiopharmacists need to keep up-to-date with the current rules and regulations. Good Radiopharmaceutical Practice (GRP) is important for Technologists to understand the steps involved towards achieving a good quality product. Some Technologists may be involved in the radiopharmacy aspect in Nuclear Medicine, thereby increasing knowledge and professional skills, leading to an enhanced practice. In this course, a clear understanding of the basics of radiopharmacy will be covered, such as differences in radionuclides, Quality Assurance and Quality Control, and the most radiopharmaceuticals used in SPECT and why these have been chosen to perform diagnostic examinations. In the second half of the mini-course, a short description of what happens in clinical trials until the product is finally injected in the patient will be shown. The timeline of events will be discussed based on the studies with a peptide labelled with 111Indium (111In- Exendin). An overview of the peptides used in clinical research will be presented. A clear description of the start of a clinical trial that develops into clinical practice will be demonstrated, using examples of patient images as illustrations.


Key Words:

Radiopharmaceutical, radionuclide, Good Radiopharmaceutical Practice (GRP), Quality Assurance (QA), Quality Control (QC), SPECT tracer, clinical trials, peptide, clinical practice.

Back to top